Compound, preparation method therefor, composition, kit and use thereof

By developing a new compound, the problem of targeting PSMA probes in the bladder and kidney retention in the prior art is solved, providing a highly specific and low renal excretion near-infrared fluorescence probe for precise localization of prostate cancer and Surgical navigation significantly improves the accuracy and safety of diagnosis and treatment.

WO2024230368A1PCT designated stage expired Publication Date: 2024-11-14DIAGPROBE BIOTECHNOLOGY (SUZHOU) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/085548
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-04-02
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing drugs targeting PSMA nuclide diagnosis and treatment and surgical navigation are severely retention in the bladder and kidneys, affecting the accuracy of early diagnosis of prostate cancer and the toxic side effects of the kidneys. They lack high specific and low renal excretion PSMA molecular imaging probes, which limits Accurate localization and grading of prostate cancer lesions.

Method used

A new compound with structures including alkali metal cations and specific alkyl groups was developed, prepared by specific synthetic methods, forming a highly specific near-infrared fluorescence probe targeting PSMA receptors for precise localization of prostate cancer and Surgical navigation.

Benefits of technology

The compound showed good recognition ability and targeting, was able to show high signal response speed and resolution in flow cytometry analysis and in vivo imaging, and had good metabolic safety and metabolic efficiency, significantly improving prostate cancer lesions and the safety of surgical resection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024085548_14112024_PF_FP_ABST
    Figure CN2024085548_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided in the present invention are a compound, a preparation method therefor, a composition, a kit, and the use thereof. The compound has a condensed structural formula as follows: wherein the cation M is selected from alkali metal cations, R is a C2-C5 alkyl, and n is an integer in the range of 2-5. The compound and an application product thereof have a good recognition ability and a good targeting performance for a PSMA receptor, can be widely applied to a plurality of scenarios such as flow cytometric analysis and in-vivo imaging in practical applications, and has the advantages of fast signal response speed, high resolution, good safety, excellent metabolic ability, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Compound, preparation method, composition, kit and application thereof

[0001] The present invention claims priority to Chinese patent application No. 202310522371.5 filed with the Patent Office of China on May 10, 2023, entitled “Compounds and their preparation methods, compositions, kits and applications”, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention belongs to the field of biological detection technology, and specifically relates to a compound and a preparation method, a composition, a kit and applications thereof. Background Art

[0003] Prostate cancer (PCa) is one of the most common tumors threatening men's health. In recent years, the incidence of prostate cancer in my country has increased significantly, becoming the fastest-growing malignant tumor. Due to the lack of sensitive imaging agents for prostate cancer diagnosis and treatment efficacy monitoring, selecting appropriate treatment options remains a major clinical challenge.

[0004] Accurate early detection of prostate cancer is crucial for patient treatment and survival. Due to its relatively slow progression, prostate cancer is often difficult to detect early. Prostate-specific antigen (PSA) combined with magnetic resonance imaging and needle biopsy can effectively diagnose PCa, but currently, there is a lack of highly sensitive and specific functional imaging devices that can define its biological behavior. Over the past decade, PET / CT has made significant progress. Combining the highly sensitive and specific nuclear medicine molecular imaging of PET with the detailed anatomical images of CT, PET / CT has demonstrated tremendous potential in preoperative diagnosis and staging of primary prostate cancer, as well as in treatment decision-making. Radical prostatectomy is one of the most effective treatments for localized and locally advanced prostate cancer. The surgeon primarily determines the extent of the resection margin based on preoperative imaging, intraoperative visual inspection and exploration, and personal experience. Excessive resection can damage normal tissue and affect normal functions such as urinary continence. On the other hand, inadequate resection can result in positive margins, making the patient more susceptible to recurrence. Therefore, how to preserve normal tissue and function as much as possible during surgery while completely removing the area invaded by prostate cancer is a problem that clinicians often need to face and solve.

[0005] Targeted fluorescence intraoperative navigation technology is a promising solution to this problem. In the field of prostate cancer, a highly specific prostate cancer molecular marker, prostate-specific membrane antigen (PSMA), exists. PSMA is overexpressed in 90% of prostate cancers, while it is only expressed in low levels in normal tissues such as the lacrimal and salivary glands and the proximal tubules of the kidneys. PSMA expression levels in prostate cancer are highly correlated with tumor invasion and malignancy. Prostate-specific membrane antigen (PSMA) is a multifunctional type II transmembrane protein composed of 750 amino acid residues, present on the prostate cell membrane. PSMA has high prostate tissue specificity, with a sensitivity and specificity of 65.9% and 94.5%, respectively, in distinguishing prostate cancer from other types of malignant tumors. Therefore, PSMA remains a highly sensitive and specific antigen on prostate cancer cells. PSMA is superior to PSA in distinguishing benign from malignant prostate tissue, and its expression increases with advanced clinical stage, positively correlating with tumor malignancy. Therefore, PSMA is a more specific prostate cancer marker than PSA and can be used as an important indicator for prostate cancer prognosis. Therefore, PSMA has become an ideal biomarker for precise positioning and imaging of prostate cancer lesions and intraoperative navigation. Near-infrared fluorescence surgical navigation technology targeting PSMA mainly utilizes the advantages of near-infrared dyes such as longer wavelength, stronger tissue penetration, and less scattering. It can illuminate the lesion during surgery, allowing the surgeon to clearly understand the scope of the lesion, thereby performing a more complete and effective resection. Therefore, near-infrared fluorescence surgical navigation targeting PSMA will be a very promising surgical method for treating prostate cancer. Furthermore, optical-nuclear medicine dual-modality molecular imaging probes can combine the advantages of two imaging modalities, with high sensitivity and high precision to identify and locate diseased tissues through nuclear medicine modalities before surgery, and accurately fluorescently mark the location of lesions during surgery to guide surgical resection.

[0006] Currently, PSMA-targeted radionuclide diagnostic and surgical navigation drugs used in clinical trials are based on a glutamic acid-urea backbone. These probes exhibit excellent targeting and affinity for PSMA, but suffer from significant radionuclide retention in the bladder and high background radionuclide levels in the kidneys. The high radionuclide retention in the bladder severely impacts the accuracy of early prostate cancer diagnosis, while the high background radionuclide levels in both kidneys can have toxic side effects. Therefore, there is an urgent need to develop highly specific PSMA molecular imaging probes with low renal excretion by modifying the drug structure. This would be crucial for the precise localization and grading of prostate cancer lesions. However, shortcomings in targeting and metabolic safety of existing probes limit their potential for widespread application.

[0007] Summary of the Invention

[0008] In order to solve all or part of the above technical problems, the present invention provides the following technical solutions:

[0009] One of the objects of the present invention is to provide a compound having the following structural formula:

[0010] The cation M is selected from an alkali metal cation, R is a C2-C5 alkyl group, and n is an integer in the range of 2-5.

[0011] In some embodiments, the cation M is selected from Na + , K + 、Li + .

[0012] In some embodiments, the preparation method of the compound comprises the following steps:

[0013] Prepare intermediate A and intermediate B, intermediate A is R is a C2-C5 alkyl group, n is an integer in the range of 2-5, and the intermediate B is The cation Q is selected from Na + , K + 、Li + ; Intermediate A and intermediate B are stirred and reacted, and then separated to obtain the target compound.

[0014] In some embodiments, the preparation of intermediate A is as follows:

[0015] A1. Prepare swollen CTC resin, react with Fmoc-Tyr(tBu)-OH / DIEA, and then deprotect to obtain intermediate 1.

[0016] B1, intermediate 1 reacts with Fmoc-NH-PEG2-CH2CH2COOH / HOBt after activation and deprotection to obtain intermediate 2;

[0017] C1, intermediate 2 and compound 1 / HBTU / HOBt react after activation, shrinkage, cracking and deprotection to obtain intermediate A, wherein compound 1 is

[0018] In some embodiments, the preparation of the intermediate B is:

[0019] A2, phosphorus trichloride reacts with DMF and cyclohexanone, the resulting mixture is mixed with ice and stirred for reaction, the precipitate is separated, washed, purified, and dried to obtain compound 2;

[0020] p-Hydrazinobenzenesulfonic acid, sodium acetate, and 3-methyl-2-butanone were stirred and reacted in acetic acid under a protective gas atmosphere, and then ether was added to precipitate, washed, and dried to obtain compound 3; the compound 3 was reacted with 1,4-butane sultone under o-dichlorobenzene and protective gas conditions, and then washed, separated, and dried to obtain compound 4;

[0021] B2, the compound 2, the compound 4 and sodium acetate are heated in methanol, and then heated with acetic anhydride for reaction, and then separated and purified at room temperature to obtain intermediate B.

[0022] In some embodiments, the stirring reaction condition is 65-75° C. for 0.5-1.5 h. Preferably, the stirring reaction condition is 70° C. for 1 h.

[0023] Furthermore, the composition includes the aforementioned compound and may also include other auxiliary ingredients such as water or an appropriate amount of sodium chloride. Auxiliary ingredients may also include a carrier, etc.

[0024] Furthermore, the kit includes the aforementioned compound or the aforementioned composition.

[0025] In some embodiments, the aforementioned compound, composition, or kit is used in a fluorescent detection material. Fluorescent detection materials include but are not limited to reagents.

[0026] In some embodiments, the aforementioned compound, composition, or kit is used in a PSMA fluorescence detection reagent.

[0027] In some embodiments, the aforementioned compound or composition is used in flow cytometry detection reagents.

[0028] Compared with existing technologies, the present invention has at least the following advantages: the compounds and their application products provided by the present invention have excellent recognition and targeting capabilities for PSMA receptors. In practical applications, they can be widely used in various scenarios such as flow cytometry analysis and in vivo imaging, with advantages such as fast signal response speed and high resolution. Furthermore, they demonstrate high resolution in flow cytometry experiments and have good metabolic safety and efficiency, which facilitates the widespread application of these products in PSMA detection technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] [Corrected 15.04.2024 according to Rule 91] Figure 1 shows the flow cytometry results according to Example 11 of the present invention;

[0030] [Corrected 15.04.2024 according to Rule 91] Figure 2 is a fluorescence metabolism diagram according to Example 11 of the present invention; [0030.1] [Corrected 15.04.2024 according to Rule 91] FIG3 is a comparison diagram of the product according to Example 11 of the present invention and the existing product OTL78; [0030.2] [Corrected 15.04.2024 according to Rule 91] Figure 4 is a fluorescence metabolism comparison chart of the product according to Example 11 of the present invention and the existing product OTL78: (a) is a 1h metabolism comparison chart; (b) is a 2h metabolism comparison chart; (c) is a 4h metabolism comparison chart; (d) is an 8h metabolism comparison chart; (e) is a 24h metabolism comparison chart; (f) is a 72h metabolism comparison chart; the circled portion in each figure is the tumor location; [0030.3] [Corrected 15.04.2024 according to Rule 91] FIG5 is a comparison chart of 2-hour in vitro tissues of the product according to Example 11 of the present invention and the existing product OTL78. DETAILED DESCRIPTION

[0031] The technical solutions of the present invention are described in detail below in conjunction with specific embodiments so that those skilled in the art can better understand and implement the technical solutions of the present invention. The specific functional details disclosed herein should not be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching those skilled in the art to employ the present invention in various ways in virtually any appropriate detailed embodiment.

[0032] Unless otherwise specified, the raw materials and reagents used in the present invention are all commercially available.

[0033] OTL78 in the prior art refers to the compound in Figure 25 of the prior art "201780067507.0".

[0034] Including but not limited to the following embodiments: Refers to the carrier resin itself, which does not participate in the reaction. eq refers to molar mass. "V" represents the volume / mass ratio. For example, in the table, 7V means that for every 1g of CTC resin used, the corresponding reagent volume is 7mL. Mice refer to BALB / c nude mice, 6-8 weeks old, weighing 18-20g; rats refer to SD rats, 8 weeks old, approximately 250g.

[0035] Example 11

[0036] Synthesis of intermediate A:

[0037] A solid-phase synthesis method was used: CTC resin was used as a fixed carrier raw material (1 g), which was first swollen in DMF for 1 h, and 3.0 equivalents (equivalent in this example refers to the mass multiple relative to CTC resin, the same below) of Fmoc-Tyr(tBu)-OH were dissolved in 7V DMF relative to the resin. Then, 6.0 equivalents (equivalent here refers to the mass multiple relative to CTC resin, the same below) of DIEA were added to hang the resin, reacted for 2 h, washed with DMF 5 times, and capped with 6 eq (eq in this example is the molar multiple relative to Fmoc-Tyr(tBu)-OH, the same below) of methanol and 10 eq (eq in this example is the molar multiple relative to Fmoc-Tyr(tBu)-OH, the same below) of DIEA. The resin was washed with DMF 4 to 5 times; then, 20% piperidine / DMF solution was added to remove the N-terminal Fmoc protecting group, making the N-terminus a free amino group, and washed with DMF 5 to 6 times to obtain intermediate 1;

[0038] 3.0 equivalents (equivalent in this example refers to the mass multiple relative to CTC resin, the same below) of Fmoc-NH-PEG2-CH2CH2COOH were dissolved in 7V DMF relative to the resin, 3.0 equivalents of HOBt were added, and 3.8 equivalents of DIC were activated for 5 min. The mixture was added to the resin and reacted under nitrogen protection for 1 h. The mixture was rinsed with DMF 4-5 times. Subsequently, the N-terminal Fmoc protecting group was removed again with 20% piperidine / DMF solution to make the N-terminal free amino group, and the mixture was rinsed with DMF 5 times to obtain intermediate 2.

[0039] The intermediate 1 (200 mg) obtained by the above solid-phase synthesis was placed in a three-necked flask, and 3.0 equivalents (equivalent in this example refers to the mass multiple relative to CTC resin, the same below) of C221211A-int2 (3-BOC-DUPA) were dissolved in 7V DMF. 3.0 equivalents of HBTU and 1.5 equivalents of HOBt were added, and 4.5 equivalents of DIEA were activated for 5 min. The mixture was added to the resin and reacted for 1 h under nitrogen protection. The mixture was rinsed with DMF 4-5 times.

[0040] Methanol was added for concentration and drying.

[0041] The target polypeptide was cleaved from the resin using a cleavage solution (trifluoroacetic acid: H2O: triisopropylsilane = 90:5:5, v / v) and the side chain protecting groups were removed (react at 20-30°C for 3 hours). The mixture was filtered and the filtrate was added to methyl tert-butyl ether to precipitate. The product was centrifuged to obtain crude C221211A-19, which was preparatively isolated and freeze-dried to obtain C221211A-19 (70 mg), intermediate A.

[0042] Purity 62.18%, LCMS: [M+H] + =643.2

[0043] Synthesis of intermediate B (dye) Synthesis of compound 2: (E)-2-chloro-3-(hydroxymethylene)cyclohex-1-enecarbaldehyde (I).

[0044] At 0°C, phosphorus oxychloride (35.0 mL, 58.8 g, 0.38 mol) was added dropwise to a dry flask containing anhydrous DMF (50 mL). Stir for 30 min, add cyclohexanone (10.5 mL, 9.98 g, 0.10 mol), and heat to 50°C for 6 hours. Subsequently, the red mixture was poured into 150 g of ice and stirred for 5 hours. The yellow precipitate was collected, washed with water, and purified with CH2Cl2. The product was collected by filtration and dried in vacuo. Compound 2 (13.5 g, 78.4 mmol, yield 77%) was obtained. LCMSm / z=173 (m+H) + .

[0045] Synthetic compound 3: Chemical name: 2,3,3-trimethyl-3H-indole-5-sulfonic acid (II)

[0046] Add p-hydrazinobenzenesulfonic acid (10.00 g, 53.2 mmol), sodium acetate (8.72 g, 106.4 mmol), 3-methyl-2-butanone (16.80 mL, 13.50 g, 156.80 mmol), and glacial acetic acid (60 mL) in sequence. Stir at 130°C under argon for 5 hours. Cool to room temperature, add diethyl ether to precipitate the product. Filter and dry in vacuo to obtain compound 3 (11.2 g, 46.8 mmol, 88%). LCMS: m / z = 240, (m+H) + .

[0047] Synthesis of compound 4: 5-sulfo-1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolium betaine (III)

[0048] Compound 3 (5.00 g, 20.92 mmol) and 1,4-butane sultone (4.91 mL, 6.54 g, 48.11 mmol) were added to 1,2-dichlorobenzene (125 mL) and stirred at 110°C under argon protection for 12 hours. After cooling to room temperature, deionized water was added to the reaction mixture to dissolve the solid matter. The aqueous phase was washed with CH2Cl2. , The organic layer was discarded.

[0049] Compound 4 (5.21 g, 13.89 mmol, 66% yield) was obtained. LCMS: m / z=375.9, (m+H) +

[0050] Synthetic intermediate B (dye).

[0051] Compound 4 (3.00 g, 8.00 mmol), compound 2 (688 mg, 4.00 mmol,) and sodium acetate (656 mg, 8.00 mol) were heated to 70 ° C in methanol (80 mL). Acetic anhydride (80 mL) was added and stirred for 8 hours. After cooling to room temperature, diethyl ether was added to the solution to precipitate. The solid precipitate was collected by filtration, dissolved in deionized water, and precipitated with 2-propanol. The solid was collected by filtration and the process was repeated twice. After vacuum drying, (dye) intermediate B (1.18 g, 1.33 mmol, 33%) was obtained. LC-MS m / z: 886.8 (M) + .

[0052] 1 H NMR (400MHz, D2O): δ = 8.35 (d, J = 14.0Hz, 2H), 7.88 (s, 2H), 7.79 (d, J = 8.4Hz, 2H), 7.34 (d, J = 8.4Hz, 2H), 6.25(d,J=14.0Hz,2H),4.17(s,4H),3.07-2.86(m,4H),2.59(s,4H),2.03-1.76(m,10H),1.72(s,12H).

[0053] Synthesis of DGPR1008:

[0054] C221211A-19 (68.6 mg, 0.1068 mmol) and C221211A-int1 (dye) (104.2 mg, 0.1068 mmol) were placed in a 25 ml single-necked vial. NaCO (67.8 mg, 0.6403 mmol) was dissolved in purified water (40 V relative to the resin) and added to the reaction flask. The mixture was stirred at 70°C for 1 hour. A sample was taken and analyzed by HPLC, with an RT of 6.930 and a purity of 40.52%. The reaction solution was then lyophilized using a 0.5% ammonium bicarbonate solution in methanol / water as the mobile phase to yield 69.2 mg of the product.

[0055] 1H NMR(400MHz,D2O)δ7.92(s,2H),7.79(s,4H),7.43-7.22(m,4H),7.19-7.02(m,2H),6.29-6.09(m,1H),4.52-4.33(m,1H),4.23-3.97(m,6H ),3.64-3.14(m,13H),3.04–2.56(m,9H),2.48–2.33(m,4H),2.33-2. 23(m,2H),2.19-1.99(m,2H),1.99-1.70(m,12H),1.43-1.30(m,12H).

[0056] Product testing:

[0057] 1. In vitro flow cytometric detection of receptor binding:

[0058] Experimental Principle

[0059] Prostate-specific membrane antigen (PSMA) is overexpressed on prostate cancer cells. Both DUPA-FITC and DGPR1008 can target the PSMA receptor in prostate cancer cells. The difference is that DUPA-FITC is linked to a visible light dye (Ex=495nm, Em=520nm), while DGPR1008 is linked to a near-infrared dye (Ex=776nm, Em=793nm). Since most lasers equipped with flow cytometers are in the visible light range, the binding force of DGPR1008 to the receptor cannot be directly measured. Therefore, DGPR1008 and DUPA-FITC are used to compete for binding to PSMA to indirectly reflect the binding force of the test compound to the receptor.

[0060] Experimental Materials

[0061] DGPR1008, DUPA-FITC, 22RV1 (PSMA+), PC3 (PSMA-), 1640 culture medium, FBS, double antibodies, trypsin, centrifuge, 4°C constant temperature incubator, flow cytometer.

[0062] Experimental methods:

[0063] Drug preparation: 100 nmol / L DUPA-FITC was prepared in culture medium. The test compound was diluted to 0.00098 μM, 0.002 μM, 0.008 μM, 0.01 μM, 0.03 μM, 0.05 μM, 0.09 μM, 0.1 μM, and 0.125 μM in culture medium containing 100 nmol / L DUPA-FITC, for a total of nine concentrations, with three replicate wells for each concentration.

[0064] Cell culture: cells were inoculated into T75 culture flasks. After 48 h, cells in logarithmic growth phase were obtained and trypsinized for 1-2 min. Fresh culture medium was added to terminate the digestion. After counting the cells, the cells were transferred into 96-well plates (1*10 5 Cells were centrifuged (800 rpm, 5 min) to discard the culture medium. The cells were rinsed twice with PBS and then centrifuged to collect the cell pellet. Nine concentrations of culture medium were added to the wells containing cells, with three replicates for each concentration. Incubate at 4°C in the dark for 30 min. The culture medium was discarded and the cells were washed twice with 300 μL of fresh culture medium and once with normal saline. The cells were then resuspended in 300 μL of normal saline for flow cytometry analysis.

[0065] The experiment showed that: as shown in Figure 1, the negative cell line PC3 had no binding ability to the PSMA receptor, the positive cell line 22RV1 had a certain binding ability to the PSMA receptor, and the target compound showed good affinity.

[0066] 2. In vivo imaging drug efficacy verification experiment

[0067] Experimental Principle

[0068] Prostate-specific membrane antigen (PSMA) is overexpressed on prostate cancer cells. The test compound is a PSMA-targeting molecule with a near-infrared I dye attached to it. The test compound binds to PSMA and "lights up" cancer cells when stimulated by a near-infrared light source. This experiment used in vivo imaging to determine the tissue distribution of the test compound in mice.

[0069] Experimental Materials

[0070] DGPR1008, 22RV1 (PSMA+), PC3 (PSMA-), 1640 culture medium, FBS, double antibodies, trypsin, Matrigel (BD), vernier caliper, centrifuge, IVIS live imager.

[0071] Experimental methods

[0072] Cell line: 22RV1 (PSMA+)

[0073] Place Matrigel on ice in advance to melt, and pre-cool the culture medium on ice. After cell centrifugation, resuspend the cells with pre-cooled culture medium and add HC Matrigel glue of equal volume to the culture medium. Place the centrifuge tube containing the cells on ice and transfer it to the animal room. Blow the cells thoroughly before inoculation. Disinfect the right shoulder of the mouse with an alcohol cotton ball and administer a single intravenous dose with an inoculation volume of 200 μL / mouse. All operations are performed on ice. The tumor volume reaches 300-400 mm 3Nine mice with well-grown, regularly shaped tumors were randomly divided into three groups: G125 nmol / mouse, G250 nmol / mouse, and G3100 nmol / mouse, with three mice in each group. Scanning times were 1, 2, 4, 8, 24, and 48 hours.

[0074] The experiment showed that, as shown in Figure 2, at the three different doses (high, medium, and low), the target compound accumulated in the prostate cancer tumor site within a certain period of time. The DGPR1008 compound demonstrated excellent targeting.

[0075] 3. Comparison with the existing product OTL78

[0076] ① In vivo imaging results and data of drug efficacy (mice were used as experimental subjects in this section)

[0077] As shown in Figure 4, in vivo imaging data comparison of OTL78 and DGPR1008:

[0078] Combining images and data, we can see that:

[0079] 1) At every time point, the fluorescence value of DGPR1008 in the tumor site was greater than that of OTL78;

[0080] 2) DGPR1008 is eliminated more slowly than OTL78 in mice;

[0081] 3) The compound of this example showed a good TBR (tumor to background ratio) within 2-4 hours.

[0082] ②2h in vitro tissue distribution results (rats were used as experimental subjects in this part):

[0083] Fluorescence ratio of tumor and normal prostate in situ:

[0084] Fluorescence unit: photon / second

[0085] in conclusion:

[0086] 1) As can be seen from the above table and Figure 5, when the compound of this example is used as a recognition aid, there is a significant signal intensity ratio between tumor and normal prostate tissue, which fully reflects the drug's ability to distinguish between normal and diseased prostate tissues;

[0087] 2) Compared with OTL78, DGPR1008 in this embodiment exhibits stronger discrimination ability (about 5 times) and higher TBR. The higher TBR can make the tumor boundary line clearer during surgery and obtain more accurate resection margins.

[0088] 3) The pharmacokinetic parameters of 2 mg / kg plasma in rats indicate that the average clearance of OTL78 is 3.50 mL / min / kg, while the average clearance of DGPR1008 in this example is 5.23 mL / min / kg, indicating that DGPR1008 is metabolized more rapidly in rats and has a correspondingly higher safety factor.

[0089] 4) In the acute toxicity test on rats, no toxic reactions were observed in the three dose groups (high, medium and low), demonstrating that the DGPR1008 compound of this example is very safe.

[0090] In summary, the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and it has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0091] Example 12

[0092] The only difference from Example 11 is: The other corresponding reagents can be adaptively adjusted by those skilled in the art.

[0093] The target compound prepared in this example is

[0094] Using the assay method described in Example 11, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound demonstrated excellent targeting. In experiments using mice as experimental subjects, the compound of this example exhibited greater fluorescence values ​​at the tumor site than OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It demonstrated enhanced discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0095] Example 13

[0096] The only difference from Example 11 is: The other corresponding reagents can be adaptively adjusted by those skilled in the art.

[0097] The target compound prepared in this example is:

[0098] Using the assay method described in Example 11, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound demonstrated excellent targeting. In experiments using mice as experimental subjects, the compound of this example exhibited greater fluorescence values ​​at the tumor site than OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It demonstrated enhanced discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0099] The intermediate 1 used in the following examples, including but not limited to, can be realized by using the technical means listed in Example 11, including but not limited to.

[0100] Example 21

[0101] The target compound prepared in this example is:

[0102] The preparation process is as follows:

[0103] Intermediate 1 (200 mg) obtained by the above solid-phase synthesis was placed in a three-necked flask, and 3.0 equivalents (equivalent in this example refers to the mass multiple of CTC resin, the same below) of Fmoc-NH-PEG3-CH2CH2COOH was dissolved in 12 mL of DMF. 3.0 equivalents of HOBt and 3.8 equivalents of DIC were added for activation for 6 min. The reaction was carried out under nitrogen protection for 1 h and rinsed with DMF four times. Subsequently, the Fmoc protecting group at the N-terminus was removed with 20% piperidine / DMF solution to convert the N-terminus into a free amino group, and the mixture was rinsed with DMF five times to obtain intermediate 22.

[0104] 3.0 equivalents of 3-BOC-DUPA were dissolved in 7V DMF relative to the resin, and activated with 3.0 equivalents of HBTU, 1.5 equivalents of HOBt, and 4.5 equivalents of DIEA for 5 min. The mixture was added to the intermediate 22 and reacted under nitrogen for 1 h. The mixture was rinsed with DMF 5 times.

[0105] Methanol was added for concentration and drying.

[0106] The target polypeptide was cleaved from the resin using a cleavage solution (trifluoroacetic acid: H2O: triisopropylsilane = 90:5:5, v / v), and the side chain protecting groups were removed (reacted at 25°C for 3 hours). The mixture was filtered, and the filtrate was added to methyl tert-butyl ether. A precipitate was precipitated and centrifuged to obtain a crude product of peptide-linked DUPA, which was preparatively isolated and freeze-dried to obtain intermediate 23.

[0107] Condensation of intermediate 23 and dye: 50 mg of intermediate 23 and dye were placed in a 25 ml single-necked bottle at a molar ratio of 1:1. 6 equivalents of Na2CO3 were dissolved in purified water (40V relative to the resin) and added to the reaction bottle. The mixture was stirred at 70°C for 1 h. The reaction solution was prepared and purified to obtain 23 mg of the product.

[0108] LCMS: [M-7Na+4H] 3+ =511.2, molecular weight of target compound sodium salt: 1690.33

[0109] 1 H NMR (400MHz, D2O): δ7.92(s,2H),7.79(s,4H),7.43-7.22(m,4H),7.19-7.02(m,2H),6.29-6.09(m,1H),4.52-4.33(m,1H),4.23-3.97(m,6H) ),3.64-3.14(m,17H),3.04–2.56(m,9H),2.48–2.33(m,4H),2.33-2. 23(m,2H),2.19-1.99(m,2H),1.99-1.70(m,12H),1.43-1.30(m,12H).

[0110] Using the assay method described in Example 11, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound demonstrated excellent targeting. In experiments using mice as experimental subjects, the compound of this example exhibited greater fluorescence values ​​at the tumor site than OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It demonstrated enhanced discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0111] Example 31

[0112] The target compound prepared in this example is:

[0113] The preparation process is as follows:

[0114] Intermediate 1 obtained by the above solid-phase synthesis was placed in a three-necked flask, and 3.0 equivalents (equivalent in this example refers to the mass multiple of CTC resin, the same below) of Fmoc-NH-(CH2CH2CH2O)2-CH2CH2COOH was dissolved in 7V DMF relative to the resin. 3.0 equivalents of HOBt and 3.8 equivalents of DIC were added for activation for 6 min. The reaction was carried out under nitrogen protection for 1 h and rinsed with DMF four times. Subsequently, the N-terminal Fmoc protecting group was removed with 20% piperidine / DMF solution to convert the N-terminal to a free amino group, and the product was rinsed with DMF five times to obtain intermediate 32.

[0115] 3.0 equivalents of 3-BOC-DUPA were dissolved in 7V DMF relative to the resin, and 3.0 equivalents of HBTU, 1.5 equivalents of HOBt, and 4.5 equivalents of DIEA were added for activation for 5 min. The mixture was added to the intermediate 32 and reacted under nitrogen for 1 h. The mixture was rinsed with DMF 5 times.

[0116] Methanol was added for concentration and drying.

[0117] The target polypeptide was cleaved from the resin using a cleavage solution (trifluoroacetic acid: H2O: triisopropylsilane = 90:5:5, v / v), and the side chain protecting groups were removed (reacted at 30°C for 3 hours). The mixture was filtered, and the filtrate was added to methyl tert-butyl ether. A precipitate was precipitated and centrifuged to obtain a crude product of peptide-linked DUPA, which was preparatively isolated and freeze-dried to obtain intermediate 33.

[0118] Condensation of intermediate 33 with dye: 50 mg of intermediate 33 and dye were placed in a 25 ml single-necked flask at a 1:1 molar ratio. 6 equivalents of NaCO dissolved in purified water (40 V relative to the resin) were added to the reaction flask and stirred at 70°C for 1 h. The reaction solution was purified to yield 35 mg.

[0119] LCMS: [M-7Na+4H] 3+ =505.6, molecular weight of target compound sodium salt: 1674.34

[0120] 1 H NMR (400MHz, D2O): δ7.92(s,2H),7.79(s,4H),7.43-7.22(m,4H),7.19-7.02(m,2H),6.29-6.09(m,1H),4.52-4.33(m,1H),4.23-3.97(m,6H) ),3.64-3.14(m,17H),3.04–2.56(m,9H),2.48–2.33(m,4H),2.33-2. 23(m,2H),2.19-1.99(m,2H),1.99-1.70(m,16H),1.43-1.30(m,12H).

[0121] Using the assay method described in Example 11, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound demonstrated excellent targeting. In experiments using mice as experimental subjects, the compound of this example exhibited greater fluorescence values ​​at the tumor site than OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It demonstrated enhanced discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0122] Example 41

[0123] The target compound prepared in this example is:

[0124] The preparation process is as follows:

[0125] Intermediate 1 (240 mg) obtained by the above solid-phase synthesis was placed in a three-necked flask, and 3.0 equivalents (equivalents in this example refer to the mass multiple of CTC resin, the same below) of Fmoc-NH-PEG3-(CH2CH2CH2O)2-CH2CH2COOH were dissolved in 12 mL of DMF. 3.0 equivalents of HOBt and 3.8 equivalents of DIC were added for activation for 6 min. The reaction was carried out under nitrogen protection for 1 h and rinsed with DMF four times. Subsequently, the Fmoc protecting group at the N-terminus was removed with 20% piperidine / DMF solution to convert the N-terminus into a free amino group, and the mixture was rinsed with DMF five times to obtain intermediate 42.

[0126] 3.0 equivalents of 3-BOC-DUPA were dissolved in 7V DMF relative to the resin, and 3.0 equivalents of HBTU, 1.5 equivalents of HOBt, and 4.5 equivalents of DIEA were added for activation for 5 min. The mixture was added to the intermediate 42 and reacted under nitrogen for 1 h. The mixture was rinsed with DMF 5 times.

[0127] Methanol was added for concentration and drying.

[0128] The target polypeptide was cleaved from the resin using a cleavage solution (trifluoroacetic acid: H2O: triisopropylsilane = 90:5:5, v / v), and the side chain protecting groups were removed (reacted at 20°C for 4 hours). The mixture was filtered, and the filtrate was added to methyl tert-butyl ether. A precipitate was precipitated and centrifuged to obtain a crude product of peptide-linked DUPA, which was preparatively isolated and freeze-dried to obtain intermediate 43.

[0129] Condensation of intermediate 43 and dye: 50 mg of intermediate 43 and dye were placed in a 25 ml single-necked bottle at a molar ratio of 1:1. 6 equivalents of Na2CO3 were dissolved in purified water (40V relative to the resin) and added to the reaction bottle. The mixture was stirred at 70°C for 1 h. The reaction solution was prepared and purified to obtain 27 mg of product.

[0130] LCMS: [M-7Na+4H] 3+ =549.6, molecular weight of target compound sodium salt: 1806.42

[0131] 1 H NMR (400MHz, D2O): δ7.92(s,2H),7.79(s,4H),7.43-7.22(m,4H),7.19-7.02(m,2H),6.29-6.09(m,1H),4.52-4.33(m,1H),4.23-3.97(m,6H) ),3.64-3.14(m,29H),3.04–2.56(m,9H),2.48–2.33(m,4H),2.33-2. 23(m,2H),2.19-1.99(m,2H),1.99-1.70(m,16H),1.43-1.30(m,12H).

[0132] Using the same assay method as described in Example 1, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound exhibited excellent targeting. In experiments using mice as experimental subjects, the fluorescence values ​​of the compound in this example at the tumor site were greater than those of OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It exhibited stronger discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0133] Example 51

[0134] The target compound prepared in this example is:

[0135] The preparation process is as follows:

[0136] Intermediate 1 (200 mg) obtained by the above solid-phase synthesis was placed in a three-necked flask, and 3.0 equivalents (equivalent in this example refers to the mass multiple of CTC resin, the same below) of Fmoc-NH-PEG2-(CH2)5O-(CH2)3O-CH2CH2COOH was dissolved in 7V DMF relative to the resin. 3.0 equivalents of HOBt and 3.8 equivalents of DIC were added for activation for 6 min. The reaction was protected by nitrogen for 1 h and rinsed with DMF four times. Subsequently, the N-terminal Fmoc protecting group was removed with 20% piperidine / DMF solution to convert the N-terminal into a free amino group, and the mixture was rinsed with DMF five times to obtain intermediate 52.

[0137] 3.0 equivalents of 3-BOC-DUPA were dissolved in 7V DMF relative to the resin, and activated with 3.0 equivalents of HBTU, 1.5 equivalents of HOBt, and 4.5 equivalents of DIEA for 5 min. The mixture was added to the intermediate 52 and reacted under nitrogen for 1 h. The mixture was rinsed with DMF 5 times.

[0138] Methanol was added for concentration and drying.

[0139] The target polypeptide was cleaved from the resin using a cleavage solution (trifluoroacetic acid: H2O: triisopropylsilane = 90:5:5, v / v), and the side chain protecting groups were removed (reacted at 30°C for 3 hours). The mixture was filtered, and the filtrate was added to methyl tert-butyl ether. A precipitate was precipitated and centrifuged to obtain a crude product of peptide-linked DUPA, which was preparatively isolated and freeze-dried to obtain intermediate 53.

[0140] Condensation of intermediate 53 and dye: 50 mg of intermediate 53 and dye were placed in a 25 ml single-necked bottle at a molar ratio of 1:1. 7 equivalents of Na2CO3 were dissolved in purified water (40V relative to the resin) and added to the reaction bottle. The mixture was stirred at 70°C for 1 h. The reaction solution was prepared and purified to obtain 35 mg of the product.

[0141] LCMS: [M-7Na+4H] 3+ =544.3, molecular weight of target compound sodium salt: 1790.42

[0142] 1 H NMR (400MHz, D2O): δ7.92(s,2H),7.79(s,4H),7.43-7.22(m,4H),7.19-7. 02(m,2H),6.29-6.09(m,1H),4.52-4.33(m,1H),4.23-3.97(m,6H),3.64- 3.14(m,25H),3.04–2.56(m,9H),2.48–2.33(m,4H),2.33-2.23(m,2H),2. 19-1.99(m,2H),1.99-1.70(m,14H),1.50-1.56(m,6H)1.43-1.30(m,12H).

[0143] Using the same assay method as described in Example 1, the target compound demonstrated strong affinity for the negative PC3 cell line, which showed no binding to the PSMA receptor, while the positive 22RV1 cell line showed some binding to the PSMA receptor. The target compound was consistently enriched in prostate cancer tumors over a period of time. The target compound exhibited excellent targeting. In experiments using mice as experimental subjects, the fluorescence values ​​of the compound in this example at the tumor site were greater than those of OTL78; its elimination in mice was slower than that of OTL78; and it exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. In experiments using rats as experimental subjects, it also exhibited a good TBR (tumor-to-background ratio) within 2-4 hours. It exhibited stronger discrimination (approximately 5-fold) and a higher TBR. This higher TBR can help define tumor boundaries during surgery and achieve more accurate resection margins. Its rapid metabolism in rats also increases the safety factor. In acute toxicity studies in rats, no toxic reactions were observed in the high, medium, and low dose groups. All these indicate that the compound of this example has a high signal-to-noise ratio in fluorescent display applications, which means it is more sensitive during surgery; and has a fast clearance rate, which means it is cleared more quickly after surgery, and has a greater safety advantage.

[0144] The various aspects, embodiments, features and examples of the present invention should be considered as illustrative in all respects and are not intended to limit the present invention, the scope of which is defined solely by the claims. Other embodiments, modifications and uses will be apparent to those skilled in the art without departing from the spirit and scope of the invention as claimed.

[0145] In addition, the inventors of this case also referred to the aforementioned embodiments and conducted experiments using other raw materials, process operations, and process conditions described in this specification, and obtained relatively ideal results.

[0146] Although the present invention has been described with reference to illustrative embodiments, it will be understood by those skilled in the art that various other changes, omissions, and / or additions may be made and that substantial equivalents may be substituted for the elements of the embodiments without departing from the spirit and scope of the present invention. Additionally, many modifications may be made to adapt specific circumstances or materials to the teachings of the present invention without departing from the scope of the present invention. Therefore, it is not intended herein to limit the present invention to the disclosed specific embodiments for carrying out the present invention, but rather to include all embodiments within the scope of the appended claims. Furthermore, unless specifically stated, any use of the terms first, second, etc. does not indicate any order or importance, but rather uses the terms first, second, etc. to distinguish one element from another.

Claims

1. A compound, the simplified structural formula of which is as follows: The cation M is selected from alkali metal cations, R is a C2-C5 alkyl group, and n is an integer in the range of 2-5.

2. The compound according to claim 1, Features: The cation M is selected from Na + , K + , Li + .

3. The method for preparing the compound according to claim 1, comprising the steps of: Prepare intermediate A and intermediate B, intermediate A is R is a C2-C5 alkyl group, n is an integer in the range of 2-5, and the intermediate B is The cation Q is selected from Na + , K + , Li + ; The intermediate A and the intermediate B are stirred and reacted, and then separated to obtain the target compound.

4. A method for preparing the compound according to claim 3, It is characterized in that The preparation of the intermediate A is as follows: A1, prepare swollen CTC resin, react with Fmoc-Tyr(tBu)-OH / DIEA, and then deprotect to obtain intermediate 1; B1, intermediate 1 and Fmoc-NH-PEG 2 -CH 2 CH 2 COOH / HOBt reacts after activation and deprotection to obtain intermediate 2; C1, intermediate 2 and compound 1 / HBTU / HOBt react after activation, shrink, cleave and deprotect to obtain intermediate A, wherein compound 1 is 5. A method for preparing the compound according to claim 3, It is characterized in that The preparation of the intermediate B is: A2, phosphorus trichloride reacts with DMF and cyclohexanone, the resulting mixture is mixed with ice and stirred for reaction, the precipitate is separated, and the precipitate is washed, purified, and dried to obtain compound 2; After hydrazinobenzenesulfonic acid, sodium acetate and 3-methyl-2-butanone are stirred in acetic acid under protective gas atmosphere for reaction, ether is added for precipitation, and the mixture is washed and dried to obtain compound 3; compound 3 is reacted with 1,4-butanesulfone under o-dichlorobenzene and protective gas conditions, and then washed, separated and dried to obtain compound 4; B2. After heating the compound 2, compound 4 and sodium acetate in methanol, acetic anhydride is added to react, and the intermediate B is obtained by separation and purification at room temperature.

6. A method for preparing the compound according to claim 3, It is characterized in that The stirring reaction condition is 65-75° C. for 0.5-1.5 h.

7. A composition comprising the compound of claim 1.

8. A kit comprising the compound of claim 1 or the composition of claim 7.

9. Use of the compound according to claim 1 or the composition according to claim 7 in a flow cytometry detection reagent.

10. Use of the compound according to claim 1, the composition according to claim 7, or the kit according to claim 8 in a fluorescent detection material.

Citation Information

Patent Citations

  • Compound as well as preparation method, composition, kit and application thereof

    CN118978470A

  • PSMA-targeted NIR dyes and their uses

    CN108135903A

  • PSMA-targeted NIR dyes and their uses

    CN110199195A

  • Prostate specific membrane antigen targeting molecular probe as well as preparation method and application thereof

    CN112961173A

  • Fluorinated Cy7 compound as well as synthesis method and application thereof

    CN113717089A